QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 acadia-pharma-faces-trial-setback-as-prader-willi-syndrome-trial-falls-short

Acadia's Phase 3 Compass Prader-Willi syndrome trial failed to meet endpoints, but the company projects $1 billion in sales...

 soleno-therapeutics-says-aware-of-serious-adverse-event-in-fdas-faers-regarding-patient-who-died-case-reported-as-not-related-to-vykat-xr-treatment-patient-was-a-17-year-old-male-who-died-from-pulmonary-embolus-vykat-xr-has-proven-safety-and-efficacy-profile

-SEC Filing

 scorpion-capital-posts-on-x-that-it-remains-short-soleno-therapeutics

https://x.com/ScorpionFund/status/1960731687903498571

 guggenheim-reiterates-buy-on-soleno-therapeutics-maintains-106-price-target

Guggenheim analyst Debjit Chattopadhyay reiterates Soleno Therapeutics (NASDAQ:SLNO) with a Buy and maintains $106 price tar...

 wells-fargo-initiates-coverage-on-soleno-therapeutics-with-overweight-rating-announces-price-target-of-123

Wells Fargo analyst Derek Archila initiates coverage on Soleno Therapeutics (NASDAQ:SLNO) with a Overweight rating and annou...

 scorpion-capital-posts-on-x-slno-soleno-therapeutics---mgmt-now-appears-to-be-copping-to-7-hospitalizations-per-guggenheim-flash-note-yesterday-if-the-hospitalizations-were-for-fluid-retention-and-potential-respiratoryheart-failure-its-hard-for-us-to-see-how-vykat-xr-has-a-viable-path-to-staying-on-the-market

https://x.com/scorpionfund/status/1957809005222330512?s=46&t=dtUiyC3dUs5yGRgT9qYHWg

 hc-wainwright--co-maintains-buy-on-soleno-therapeutics-raises-price-target-to-110

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Soleno Therapeutics (NASDAQ:SLNO) with a Buy and raises the pri...

 soleno-under-serious-scrutiny-as-short-seller-alleges-pws-drug-is-overpriced-unsafe

Children were reportedly hospitalized after starting treatment. Scorpion Capital suggests Soleno's medication could face ma...

 guggenheim-maintains-buy-on-soleno-therapeutics-raises-price-target-to-106

Guggenheim analyst Debjit Chattopadhyay maintains Soleno Therapeutics (NASDAQ:SLNO) with a Buy and raises the price target f...

 oppenheimer-maintains-outperform-on-soleno-therapeutics-raises-price-target-to-110

Oppenheimer analyst Leland Gershell maintains Soleno Therapeutics (NASDAQ:SLNO) with a Outperform and raises the price targe...

 soleno-therapeutics-q2-eps-009-beats-090-estimate

Soleno Therapeutics (NASDAQ:SLNO) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $...

 baird-maintains-outperform-on-soleno-therapeutics-raises-price-target-to-121

Baird analyst Brian Skorney maintains Soleno Therapeutics (NASDAQ:SLNO) with a Outperform and raises the price target from $...

 soleno-therapeutics-prices-200m-public-offering-of-2352941-shares-at-85share

Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment o...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION